Advertisement

Topics

Efficiency of Antibacterial Prophylaxis in Azacitidine Treated Patients

2018-07-26 12:30:16 | BioPortfolio

Published on BioPortfolio: 2018-07-26T12:30:16-0400

Clinical Trials [609 Associated Clinical Trials listed on BioPortfolio]

Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes

RATIONALE: Drugs used in chemotherapy, such as decitabine, work in different ways to stop the growth of myelodysplastic cells, either by killing the cells or by stopping them from dividing...

Prospective Study of Molecular Predictors of Survival in Myelodysplastic Syndromes

This study aims at prospectively enrolling a cohort of 400 incident cases of myelodysplastic syndromes (MDS) at diagnosis, to evaluate the impact of recurrent mutations on overall survival...

Combination of 5-Azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic Syndromes

The hypothesis of this study is that 5-aza and lenalidomide act synergistically in MDS and AML patients with chromosomal abnormalities involving monosomy 5 or del5q. Therefore, this phase ...

A Study of Decitabine Given to Adults With Advanced-Stage Myelodysplastic Syndromes

The purpose of this study is to determine the overall response rate in patients with myelodysplastic syndromes (MDS) given a daily dosing schedule of decitabine.

A Study to Access the Safety/Efficacy of Thalidomide in the Treatment of Anemia in Patients With Myelodysplastic Syndromes

The primary objective of the study is to determine the efficacy of thalidomide for the treatment of anemia in patients with myelodysplastic syndromes (MDS).

PubMed Articles [797 Associated PubMed Articles listed on BioPortfolio]

Evaluation of bone marrow microenvironment could change how myelodysplastic syndromes are diagnosed and treated.

Myelodysplastic syndromes are a heterogeneous group of clonal hematopoietic disorders. However, the therapies used against the hematopoietic stem cells clones have limited efficacy; they slow the evol...

Disordered Immune Regulation and its Therapeutic Targeting in Myelodysplastic Syndromes.

Immune dysregulation is a defining feature of myelodysplastic syndromes (MDS). Recently, several studies have further defined the complex role of immune alterations within MDS. Herein, we will summari...

Myelodysplastic syndromes in children.

Myelodysplastic syndromes (MDSs) are rare disorders in children, showing peculiar clinical manifestations and biological features. This review will summarize biological, genetic and clinical features ...

Myelodysplastic Syndromes: Laboratory Workup in the Context of New Concepts and Classification Criteria.

This review provides a comprehensive update of myelodysplastic syndromes (MDS) and their diagnostic criteria, with emphasis on novel concepts and state-of-the-art laboratory workup, including multipar...

Inflammatory disorders associated with trisomy 8-myelodysplastic syndromes: French retrospective case-control study.

We report cases of myelodysplastic syndrome/myeloproliferative neoplasms (MDS/MPN) with trisomy 8 associated with inflammatory and autoimmune diseases (IADs).

Medical and Biotech [MESH] Definitions

Clonal myeloid disorders that possess both dysplastic and proliferative features but are not properly classified as either MYELODYSPLASTIC SYNDROMES or MYELOPROLIFERATIVE DISORDERS.

These growth factors comprise a family of hematopoietic regulators with biological specificities defined by their ability to support proliferation and differentiation of blood cells of different lineages. ERYTHROPOIETIN and the COLONY-STIMULATING FACTORS belong to this family. Some of these factors have been studied and used in the treatment of chemotherapy-induced neutropenia, myelodysplastic syndromes, and bone marrow failure syndromes.

Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.

Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.

The L-isomer of Ofloxacin.

More From BioPortfolio on "Efficiency of Antibacterial Prophylaxis in Azacitidine Treated Patients"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial